Advanced Biomed (ADVB) Cash & Equivalents (2023 - 2026)

Advanced Biomed has reported Cash & Equivalents for 4 years, with the latest figure at $2.6 million in Q1 2026.

• Quarterly Cash & Equivalents fell 18.06% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 million (down 18.06% YoY) and the FY2025 annual result came in at $2.9 million, up 9.94% from the prior year.
• Cash & Equivalents steadied at $2.6 million in Q1 2026 per ADVB's latest filing, from $2.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $3.2 million in Q1 2025 and troughed at $9579.0 in Q4 2024.
• A 4-year average of $2.5 million and a median of $2.7 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents plunged 99.66% in 2024, then jumped 27091.42% in 2025.
• Over 4 years, Cash & Equivalents stood at $2.8 million in 2023, then slumped by 99.66% to $9579.0 in 2024, then surged by 27091.42% to $2.6 million in 2025, then declined by 0.08% to $2.6 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $2.6 million, $2.6 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.